natgillin/translations-raw huggingface dataset:
In certain situations, for example if you are 75 years or older, your doctor may recommend a starting dose of mg once a week.
U određenim situacijama, primjerice ako imate 75 ili više godina, liječnik će Vam možda preporučiti početnu dozu od 0,75 mg jedanput na tjedan.
In CHAMPION PHOENIX, cangrelor significantly reduced (relative risk reduction 22%; absolute risk reduction 1.2%) the primary composite endpoint of all-cause mortality, MI, IDR, and ST compared to clopidogrel at 48 hours (Table 3).
U ispitivanju CHAMPION PHOENIX, kangrelor je značajno smanjio (smanjenje relativnog rizika 22%; smanjenje apsolutnog rizika 1,2%) primarni kompozitni ishod mortaliteta svih uzroka, infarkta miokarda (MI), revaskularizacije potaknute ishemijom (IDR) i tromboze stenta (ST) u usporedbi s klopidogrelom nakon 48 sati (Tablica 3).
In childhood cancer survivors, an increased risk of a second neoplasm has been reported in patients treated with somatropin after their first neoplasm.
Zabilježen je povećani rizik od druge novotvorine kod bolesnika koji su preživjeli karcinom u djetinjstvu, ako su liječeni somatotropinom nakon njihove prve novotvorine.
In children (6 years of age or older) treated for Crohn’s disease or ulcerative colitis, the recommended dose is the same as for adults.
Preporučena doza u djece (starosti 6 ili više godina) za liječenje Crohnove bolesti ili ulceroznog kolitisa je ista kao i doza koja je preporučena za odrasle.
In children 12 to 23 months of age, the vaccine may also be administered in the anterolateral part of the thigh (see sections 4.4 and 4.5).
U djece u dobi od 12 do 23 mjeseca, cjepivo se također može primijeniti u anterolateralni dio bedra (vidjeti dijelove 4.4 i 4.5).
In children 3 to 9 years of age who received two 0.25 ml doses of Pandemrix (H1N1) the side effects reported were similar to those reported in adults, except for redness at the injection site and gastrointestinal symptoms which were very common and shivering and sweating which were common.
U djece u dobi od 3 do 9 godina koja su primila dvije doze od 0.25 ml Pandemrixa (H1N1), prijavljene nuspojave su slične onima u odraslih, osim crvenila na mjestu injiciranja i probavnih simptoma koji su bili vrlo česti te drhtanja i znojenja koji su bili česti.
In children 6-16 years of age the lung deposition falls in the same range as in adults for the same given dose.
Odlaganje lijeka u plućima u djece u dobi od 6- 16 godina u istom je rasponu kao ono u odraslih za istu primijenjenu dozu.
In children < 3 years old that mainly suffer from PCG (primary congenital glaucoma), surgery (e.g. trabeculotomy/goniotomy) remains the first line treatment.
U djece < 3 godine starosti koja većinom boluju od primarnog kongenitalnog glaukoma, kirurški zahvat (npr. trabekulotomija/goniotomija) ostaje prva linija liječenja.
In children aged 1 to 17 years, the recommended dose is 10 mg three times a day in children weighing less than 20 kg and 20 mg three times a day in those over 20 kg.
U djece u dobi od 1 do 17 godina, preporučena doza je 10 mg tri puta na dan u djece s tjelesnom težinom manjom od 20 kg i 20 mg tri puta na dan u djece s tjelesnom težinom većom od 20 kg.
In children aged 12-23 months, the immune responses elicited after two doses were comparable to the responses elicited after three doses in infants below 6 months of age, except for vaccine serotypes 18C and 19F as well as serotype 19A for which responses were higher in the 12-23 months children.
U djece u dobi od 12 do 23 mjeseca, imunološki odgovori postignuti nakon dvije doze bili su usporedivi s odgovorima nastalima nakon tri doze u dojenčadi mlađe od 6 mjeseci, osim za serotipove 18C i 19F sadržane u cjepivu kao i za serotip 19A za koje su odgovori bili veći u djece u dobi od 12 do 23 mjeseca.
In children aged 2 months to <3 years, the following side effects have been observed more frequently compared to children aged 3 years to <12 years, adolescents and adults:
Kod djece u dobi od 2 mjeseca do <3 godine sljedeće su nuspojave primijećene češće u usporedbi s djecom u dobi od 3 godine do < 12 godina, adolescentima i odraslima:
In children aged 2 to 5 years the most common side effects are nasal congestion (26.5 %), upper respiratory tract infection (23.5 %), increase in liver enzymes (14.7 %), rash (11.8 %) and bacteria in sputum (11.8 %).
U djece u dobi od 2 do 5 godina najčešće nuspojave su začepljen nos (26,5 %), infekcija gornjih dišnih puteva (23,5 %), povećanje jetrenih enzima (14,7 %), osip (11,8 %) i bakterije u ispljuvku (11,8 %).
In children aged between two months and three years, half the adult dose of Ixiaro (0.25 ml) should be given, and an additional 0.25 ml dose should be given four weeks later.
U djece u dobi između dva mjeseca i tri godine, polovicu doze lijeka Ixiaro koja se daje odraslim osobama (0,25 ml) treba dati odmah, a dodatnu dozu od 0,25 ml treba dati nakon četiri tjedna.
In children aged from 2 months to 9 months plasma concentrations of retapamulin were measurable in 69% (20/29) of samples.
Među djecom u dobi od 2 mjeseca do 9 mjeseci, koncentracija retapamulina u plazmi bila je mjerljiva u 69% (20/29) uzoraka.
In children aged less than 3 years, fever, diarrhoea, influenza-like illness, irritability and redness at injection site were the most common side effects (seen in more than 1 of 10 children) and in children aged 3 years and older, fever and injection site pain and tenderness were most common.
U djece mlađe od 3 godine najčešće su nuspojave bile vrućica, proljev, bolest slična influenci, nadraženost i crvenilo na mjestu injekcije (uočene u više od 1 na 10 djece), a u djece u dobi od 3 godine i starije najčešće su nuspojave bile vrućica te bol i osjetljivost na mjestu injekcije.
In children ages 6 – 17 years old, side effects were consistent with those described below with the following exceptions: pneumonia, dehydration, sweating decreased (common) and abnormal liver enzymes (uncommon).
U djece u dobi od 6 do 17 godina, nuspojave su se podudarale s niže opisanima uz sljedeće iznimke: upala pluća, dehidracija, smanjeno znojenje (često) i poremećeni jetreni enzimi (manje često).
In children ages 6 – 17 years old, side effects were consistent with those described below with the following exceptions: pneumonia, dehydration, sweating decreased (common), abnormal liver enzymes (uncommon), middle ear infection, sore throat, sinus and chest infections, cough, nosebleeds, runny nose, stomach pain, vomiting, rash, eczema and fever.
U djece u dobi od 6 do 17 godina, nuspojave su se podudarale s niže opisanima uz sljedeće iznimke: upala pluća, dehidracija, smanjeno znojenje (često) i poremećeni jetreni enzimi (manje često), infekcija srednjeg uha, bol u grlu, infekcije u sinusima i u prsima, kašalj, krvarenje iz nosa, curenje iz nosa, bol u trbuhu, povraćanje, osip, ekcem i vrućica.
In children and adolescent patients 1st dose reduction of PegIntron is to 40 µg/m2/week, 2nd dose reduction of PegIntron is to 20 µg/m2/week.
U djece i adolescenata prvo smanjenje doze lijeka PegIntron je na 40 μg/m2 na tjedan, a drugo smanjenje doze lijeka PegIntron je na 20 μg/m2 na tjedan.
In children and adolescent patients 1st dose reduction of PegIntron is to 40 g/m2/week, 2nd dose reduction of PegIntron is to 20 g/m2/week.
U djece i adolescenata prvo smanjenje doze lijeka PegIntron je na 40 μg/m2 na tjedan, a drugo smanjenje doze lijeka PegIntron je na 20 μg/m2 na tjedan.
In children and adolescent patients 1st dose reduction of ribavirin is to 12 mg/kg/day, 2nd dose reduction of ribavirin is to 8 mg/kg/day.
U djece i adolescenata prvo smanjenje doze ribavirina je na 12 mg/kg na dan, a drugo smanjenje doze ribavirina je na 8 mg/kg na dan.
In children and adolescent patients 1st dose reduction of ViraferonPeg is to 40 g/m2/week, 2nd dose reduction of ViraferonPeg is to 20 g/m2/week.
U djece i adolescenata prvo smanjenje doze lijeka ViraferonPeg je na 40 μg/m2 na tjedan, a drugo smanjenje doze lijeka ViraferonPeg je na 20 μg/m2 na tjedan.
In children and adolescent patients treated with Ribavirin Mylan plus interferon alfa-2b, reduce Ribavirin Mylan dose to 7.5 mg/kg/day.
U oboljele djece i adolescenata koji se liječe lijekom Ribavirin Mylan u kombinaciji s interferonom alfa•2b smanjite dozu lijeka Ribavirin Mylan na 7,5 mg/kg/dan.
In children and adolescent patients treated with Ribavirin Teva Pharma B.V. plus interferon alfa-2b, reduce ribavirin dose to 7.5 mg/kg/day.
U oboljele djece i adolescenata koji se liječe kombiniranom terapijom lijeka Ribavirin Teva Pharma B.V. i interferona alfa-2b smanjite dozu ribavirina na 7,5 mg/kg/dan.
In children and adolescent PNH patients (aged 11 years to less than 18 years) included in the paediatric PNH Study M07-005, the safety profile appeared similar to that observed in adult PNH patients.
U djece i adolescenata s PNH-om (u dobi od 11 godina do manje od 18 godina) uključenih u pedijatrijsko PNH ispitivanje M07-005, sigurnosni profil činio se sličnim onom u odraslih bolesnika s PNH-om.
In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2 %), agitation (common, 3.4 %), mood swings (common, 2.1 %), affect lability (common, 1.7 %), aggression (common, 8.2 %), abnormal behaviour (common, 5.6 %), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile.
U djece i adolescenata u dobi 4 do 16 godina povraćanje (vrlo često, 11,2%), agitacija (često, 3,4%), promjene raspoloženja (često, 2,1%), labilnost afekta (često, 1,7%), agresija (često, 8,2%), poremećaj ponašanja (često, 5,6%) i letargija (često, 3,9%) bili su prijavljeni češće nego u drugim dobnim rasponima ili u cjelokupnom sigurnosnom profilu.
In children and adolescents however it may be used to treat all stages of the illness.
U djece i adolescenata može se koristiti za liječenje svih faza bolesti.
In children and adolescents its use is only for those who cannot be treated with other first-line nucleotide reverse transcriptase inhibitors (NRTI).
Indiciran je u djece i adolescenata samo u slučaju onih bolesnika koji se ne mogu liječiti drugim nenukleozidnim inhibitorima povratne transkriptaze (NRTI) predviđenima za prvu liniju liječenja.
In children and adolescents with Sickle Cell Syndrome, systemic exposure to hydroxycarbamide is similar to adult patients.
Kod djece i adolescenata sa sindromom anemije srpastih stanica sistemska izloženost hidroksikarbamidu slična je kao i kod odraslih bolesnika.
In children and adolescents, glucose monitoring should be intensified and the Levemir dose adjusted on an individual basis.
U djece i adolescenata treba pojačano pratiti razine glukoze te individualno prilagoditi dozu lijeka Levemir.
in children below 2 years of age, who may be at greater risk of side effects from any of the medicine absorbed through the skin. if you are taking certain medicines used for depression or Parkinson’s disease including so-called monoamine oxidase (MAO) inhibitors (for example selegiline or moclobemide) or tricyclic antidepressants (such as imipramine) or tetracyclic antidepressants (such as maprotiline, mianserin or mirtazapin).
u djece mlađe od 2 godine, koja mogu imati veći rizik od nuspojava s bilo kojim lijekom koji se upija kroz kožu. ako uzimate određene lijekove koji se koriste kod depresije ili Parkinsonove bolesti uključujući takozvane inhibitore monoaminooksidaze (MAO) (na primjer selegilin ili moklobemid), ili triciklične antidepresive (poput imipramina) ili tetraciklične antidepresive (poput maprotilina, mianserina ili mirtazapina).
In children between 6 months and 12 years of age, Emend oral suspension is given together with a 5- HT3 antagonist.
U djece u dobi od 6 mjeseci do 12 godina oralna suspenzija Emend daje se zajedno s antagonistom 5- HT3.
In children less than 10 years of age, the daily dose is 100 mg/kg/day given in 2 doses.
Za djecu mlađu od 10 godina dnevna doza je 100 mg/kg/dan, podijeljeno u 2 doze.
in children on haemodialysis
u djece na hemodijalizi
In children over 12 years old with Primary IGFD and in healthy adults there were no apparent differences between males and females in the pharmacokinetics of INCRELEX.
Kod djece dobi preko 12 godina s teškom primarnom deficijencijom IGF i kod zdravih odraslih osoba nije bilo očitih razlika između muškaraca i žena u farmakokinetici INCRELEXA.
In children the most common side effects (seen in more than 1 patient in 10) are vomiting, cough and nasal congestion (a blocked nose).
U djece su najčešće nuspojave (uočene kod 1 na 10 bolesnika) bile povraćanje, kašalj i kongestija nosa (začepljen nos).
In children under 18 years of age, there is a possible association between ASA and Reye’s syndrome.
U djece mlađe od 18 godina zbog moguće povezanosti između uzimanja ASK i pojave Reyeovog sindroma.
In children up to 17 years of age, the recommended dose of Busulfan Fresenius Kabi varies between 0.8 and 1.2 mg per kilogram depending on the weight of the child.
U djece starosti do 17 godina preporučena doza lijeka Busulfan Fresenius Kabi varira između 0,8 i 1,2 mg/kg ovisno o tjelesnoj težini djeteta.
In children weighing at least 40 kg, Simponi is used for the treatment of polyarticular juvenile idiopathic arthritis.
U djece tjelesne težine od najmanje 40 kg Simponi se koristi za liječenje poliartikularnog juvenilnog idiopatskog artritisa.
In children who are at risk of aspiration, aged approximately 6 years and under, the hard capsules should be opened and the content sprinkled on food.
U djece kod koje postoji rizik od aspiracije, u dobi oko 6 godina i mlađoj, tvrde kapsule treba otvoriti, a sadržaj posipati po hrani.
In children who are unable to swallow capsules, these should be opened and their content suspended in a little water (possibly sugar or syrup flavoured water).
Kod djece koja nisu u stanju pogutati kapsule, treba ih otvoriti i njihov sadržaj pomiješati u malo vode (u koju može biti dodan šećer ili sirup).
In children whose mothers took medicines like Viread (NRTIs) during pregnancy, the benefit from the protection against the virus outweighed the risk of side effects.
U djece čije su majke tijekom trudnoće uzimale lijekove kao što je Viread (NRTI) prevagnula je korist od zaštite protiv virusa u odnosu na rizike od nuspojava.
In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
U djece čije su majke tijekom trudnoće uzimale NRTI-jeve prevagnula je korist od zaštite protiv HIV-a u odnosu na rizike od nuspojava..
In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
U djece čije su majke tijekom trudnoće uzimale nukleozidne inhibitore reverzne transkriptaze (NRTI) korist zaštite od HIV-a nadmašuje rizik od nuspojava.
In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
U djece čije su majke tijekom trudnoće uzimale nukleozidne inhibitore reverzne transkriptaze (NRTI), korist zaštite od HIV-a nadmašuje rizik od nuspojava..
In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
U djece čije su majke tijekom trudnoće uzimale nukleozidne inhibitore reverzne transkriptaze (NRTIs), korist od zaštite od infekcije virusom HIV-a prevagnula je u odnosu na rizik od nuspojava.
In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
U djece čije su majke tijekom trudnoće uzimale nukleozidne inzhibitore reverzne transkriptaze (NRTI), korist zaštite od HIV-a nadmašuje rizik od nuspojava.
In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIVoutweighed the risk of side effects.
U djece čije su majke tijekom trudnoće uzimale NRTI-jeve prevagnula je korist od zaštite protiv HIV-a u odnosu na rizike od nuspojava.
In children with chronic hepatitis C, the effectiveness of 48 weeks of treatment with Pegasys and ribavirin was examined in 55 children in one main study.
U djece s kroničnim hepatitisom C, djelotvornost 48-tjednog liječenja lijekom Pegasys i ribavirinom ispitana je u 55 djece u jednom glavnom ispitivanju.
In children with chronic ITP, Revolade was compared with placebo in one main study involving a total of 92 children between 1 and 17 years of age who had previously received treatment for ITP.
Kod djece s kroničnim ITP-om lijek Revolade uspoređen je s placebom u jednom glavnom ispitivanju na sveukupno 92 djece u dobi između 1 i 17 godina koja su prethodno primila terapiju protiv ITP-a.
In children with complicated skin or soft tissue infections aged 7 to 17 years, Cubicin is given as an infusion lasting 30 minutes, whereas in children aged 1 to 6 years the infusion should last 60 minutes.
U djece u dobi između sedam i 17 godina s kompliciranim infekcijama kože ili mekog tkiva Cubicin se daje u obliku infuzije koja traje 30 minuta, dok bi u djece u dobi između jedne i šest godina infuzija trebala trajati 60 minuta.
In children with diabetes, blood glucose monitoring should be increased.
Kod djece s dijabetesom, praćenje glukoze u krvi mora biti učestalije.
In children with growth hormone deficiency:
Kod djece s nedostatkom hormona rasta:
In children, 51.5% (52 out of 101) of the study participants had a viral load below 50 copies/ml after 24 weeks of taking Intelence, and this was slightly increased after 48 weeks.
U djece, 51,5% (52 od 101) sudionika ispitivanja imalo je virusno opterećenje manje od 50 kopija/ml nakon 24 tjedana uzimanja lijeka Intelence, a ova je vrijednost neznatno povećana nakon 48 tjedana.
In children, accidental ingestion should be regarded as serious.
Slučajno gutanje u djece treba smatrati ozbiljnim.
In children, administration of tablets delivered higher plasma lamivudine AUC∞ and Cmax than oral solution.
U djece je primjena tableta dovela do viših plazmatskih vrijednosti AUC∞ i Cmax lamivudina nego oralna otopina.
In children, care should be taken to match insulin doses (especially in basal-bolus regimens) with food intake and physical activities in order to minimise the risk of hypoglycaemia.
Doze inzulina u djece potrebno je oprezno uskladiti (osobito u sklopu bazal-bolus inzulinske terapije) s unosom hrane i tjelesnom aktivnošću kako bi se umanjio rizik od hipoglikemije.
In children, four weeks after the final injection, 99% to 100 % of children who received both doses of Ixiaro had developed protective levels of antibodies.
U djece, četiri tjedna nakon posljednje injekcije 99 % do 100 % djece koja su primila obje doze lijeka Ixiaro razvilo je zaštitne razine protutijela.
In children, symptoms of accidental overdose included ataxia, dizziness, vomiting, rash, diarrhea, tremor, and flushing, and elevation in alkaline phosphatase.
Simptomi slučajnog predoziranja u djece uključivali su ataksiju, omaglicu, povraćanje, osip, proljev, tremor, crvenilo kože i porast vrijednosti alkalne fosfataze.
In children, the dose depends on body weight and ranges from 100 mg twice a day to 200 mg twice a day.
U djece doza ovisi o tjelesnoj težini i varira od 100 mg dva puta na dan do 200 mg dva puta na dan.
In choroidal neovascularisation due to pathologic myopia, on average in the first 3 months of treatment, patients given Lucentis could see around 8-9 letters more than those receiving verteporfin PDT.
Kod koroidne neovaskularizacije uzrokovane patološkom miopijom u prosjeku su u prva tri mjeseca liječenja bolesnici kojima je davan Lucentis mogli vidjeti približno 8-9 slova više d onih koji su primali verteporfin PDT.
In chronic hepatitis B in adults, two studies have been carried out comparing Pegasys with lamivudine (another antiviral medicine) in 820 ‘HBeAg-positive’ patients (infected with the common type of the hepatitis B virus) and in 552 ‘HBeAg-negative’ patients (infected with a virus that has mutated [changed], leading to a form of chronic hepatitis B that is more difficult to treat).
Kod kroničnog hepatitisa B u odraslih bolesnika provedena su dva ispitivanja koja su uspoređivala lijek Pegasys s lamivudinom (drugim antivirusnim lijekom) u 820 „HBeAg-pozitivna” bolesnika (zaražena čestim tipom virusa hepatitisa B) te u 552 „HBeAg-negativna” bolesnika (zaražena virusom koji je mutirao [promijenio se], što je dovelo do razvoja oblika hepatitisa B koji je teže liječiti).
In chronic hepatitis B or C patients, peginterferon alfa-2a serum concentrations accumulate 2 to 3 fold after 6 to 8 weeks of once weekly dosing compared to single dose values.
Kod bolesnika s kroničnim hepatitisom B ili C koncentracije peginterferona alfa-2a akumuliraju se u serumu 2 do 3 puta više nakon 6 do 8 tjedana primjene jedanput tjedno, nego kod jednokratne primjene.
In chronic hepatitis B, Pegasys was more effective than lamivudine in both HBeAg-positive and negative patients.
Kod kroničnog hepatitisa B Pegasys se pokazao djelotvornijim od lamivudina i kod HBeAg pozitivnih i negativnih bolesnika.
In chronic hepatitis B, unlike chronic hepatitis C, disease exacerbations during therapy are not uncommon and are characterised by transient and potentially significant increases in serum ALT.
Pogoršanje bolesti tijekom liječenja kroničnog hepatitisa B, za razliku od kroničnog hepatitisa C, nije rijetko i karakteriziraju ga kratkotrajna i potencijalno znatna povećanja razina ALT-a u serumu.
In chronic hepatitis C clinical trials with adult patients, isolated increases in ALT (≥ 10x ULN, or ≥ 2x BL for patients with a BL ALT ≥ 10x ULN) which resolved without dose-modification were observed in 8 of 451 patients treated with combination therapy.
U kliničkim ispitivanjima kroničnog hepatitisa C u odraslih bolesnika, u 8 od 451 bolesnika koji su primali kombinaciju lijekova, zamijećeni su izolirani slučajevi povećanje razina ALT-a (10x od gornje granice normale, odnosno ≥2x od početne vrijednosti u bolesnika čija je početna vrijednosti ALT-a bila 10x od gornje granice normale) koje je riješeno bez promjene doze.
In chronic hepatitis C in adults, Pegasys has been studied on its own in three studies involving a total of 1,441 patients, and in combination with ribavirin in one study involving 1,149 patients.
Kod odraslih bolesnika s kroničnim hepatitisom C Pegasys je proučavan sam u trima ispitivanjima koja su uključivala ukupno 1441 bolesnika te u kombinaciji s ribavirinom u jednom ispitivanju koje je uključivalo 1149 bolesnika.
In chronic hepatitis C in adults, Pegasys on its own was more effective than interferon alfa-2a.
Kod kroničnog hepatitisa C u odraslih, sam Pegasys bio je djelotvorniji od interferona alfa-2a.
In chronic iron overload due to blood transfusions, Exjade was investigated in one main study comparing Exjade with deferoxamine in 591 patients with beta thalassaemia major.
U bolesnika s kroničnim preopterećenjem željezom zbog transfuzija krvi lijek Exjade ispitivan je u okviru jednoga glavnog ispitivanja u kojemu je lijek Exjade uspoređivan s deferoksaminom na 591 bolesniku s beta-talasemijom major.
In Chronic Kidney Disease (CKD) patients receiving dialysis who were administered cinacalcet, approximately 30% of patients had at least one serum calcium value less than 7.5 mg/dl (1.9 mmol/l).
U bolesnika s kroničnom bolesti bubrega na dijalizi koji su liječeni sinakalcetom, otprilike 30% bolesnika imalo je najmanje jednu vrijednost serumskog kalcija manju od 7,5 mg/dl (1,9 mmol/l).
In chronic lymphocytic leukaemia and Waldenström’s macroglobulinaemia, the recommended dose is 3 capsules once a day, whereas in mantle cell lymphoma it is 4 capsules once a day.
U slučaju kronične limfocitne leukemije i Waldenströmove makroglobulinemije, preporučena doza iznosi 3 tablete jednom na dan, dok u slučaju limfoma plaštenih stanica doza iznosi 4 tablete jednom na dan.
In chronic renal failure patients the rate of increase in haemoglobin should be approximately 1 g/dl (0.62 mmol/l) per month and should not exceed 2 g/dl (1.25 mmol/l) per month to minimise risks of an increase in hypertension.
U bolesnika s kroničnim zatajenjem bubrega brzina porasta hemoglobina treba iznositi približno 1 g/dl (0,62 mmol/l) na mjesec i ne smije biti veća od 2 g/dl (1,25 mmol/l) na mjesec, kako bi se minimalizirali rizici od povišenja hipertenzije.